REFERENCES
1. De Dombal FT. Ulcerative colitis: definition, historical background, aetiology, diagnosis, naturel history and local complications. Postgrad Med J. 1968;44(515):684.
2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. The Lancet. 2007;369(9573):1627–40.
3. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. Am J Med. 1952;13(5):583–90.
4. Gower-‐Rousseau C, Salomez JL, Dupas JL, Marti R, Nuttens MC, Votte A, et al. Incidence of inflammatory bowel disease in northern France (1988-‐1990). Gut. 1994;35(10):1433–8.
5. Satsangi J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006 Jun 1;55(6):749–53.
6. Louis E, Collard A, Oger AF, Degroote E, El Yafi FAN, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut.
2001;49(6):777–82.
7. Tremaine WJ. Is Indeterminate Colitis Determinable? Curr Gastroenterol Rep. 2012 Apr;14(2):162–5.
8. Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955–1989. Gut. 1997;41(4):480–6.
9. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004 May;126(6):1504–17.
10. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease.
Nature. 2007 Jul 26;448(7152):427–34.
11. Budarf ML, Labbé C, David G, Rioux JD. GWA studies: rewriting the story of IBD. Trends Genet. 2009 Mar;25(3):137–46.
12. Chouraki V, Savoye G, Dauchet L, Vernier-‐Massouille G, Dupas J-‐L, Merle V, et al. The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10-‐ to 19-‐year-‐old age bracket (1988-‐2007): Epidemiology of inflammatory bowel disease. Aliment Pharmacol Ther. 2011 May;33(10):1133–42.
13. Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, et al.
Incidence of juvenile-‐onset Crohn’s disease in Scotland: Association with northern latitude and affluence. Gastroenterology. 2004 Oct;127(4):1051–7.
14. Phavichitr N, Cameron DJ, CATTO-‐SMITH A. Increasing incidence of Crohn’s disease in Victorian children. J Gastroenterol Hepatol. 2003;18(3):329–32.
15. Loftus Jr EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR.
Crohn’s disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114(6):1161–8.
16. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-‐fold rise in Crohn’s disease.
Gut. 1989 May;30(5):618–22.
17. Gower-‐Rousseau C, Dauchet L, Vernier-‐Massouille G, Tilloy E, Brazier F, Merle V, et al. The natural history of pediatric ulcerative colitis: a population-‐based cohort study. Am J Gastroenterol. 2009 Aug;104(8):2080–8.
18. Declercq C, Gower-‐Rousseau C, Vernier-‐Massouille G, Salleron J, Baldé M, Poirier G, et al.
Mapping of inflammatory bowel disease in northern France: Spatial variations and relation to affluence: Inflamm Bowel Dis. 2010 May;16(5):807–12.
19. Molinie F. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis in Northern France (1988-‐1999). Gut. 2004 Jun 1;53(6):843–8.
20. Cosgrove M, Al-‐Atia RF, Jenkins HR. The epidemiology of paediatric inflammatory bowel disease. Arch Dis Child. 1996;74(5):460–1.
21. Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-‐based study: Incidence of inflammatory bowel disease. J Gastroenterol Hepatol. 2013 Jul;28(7):1148–53.
22. Sedlack RE, Whisnant J, Elveback LR, Kurland LT. Incidence of Crohn’s disease in Olmsted County, Minnesota, 1935-‐1975. Am J Epidemiol. 1980 Dec;112(6):759–63.
23. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-‐2000. Inflamm Bowel Dis. 2007 Mar;13(3):254–61.
24. Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-‐Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn’s disease in the County of Copenhagen, 1962 to 1978. Gastroenterology. 1982 Sep;83(3):563–8.
25. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962-‐87: a sixfold increase in incidence.
Scand J Gastroenterol. 1992 Jul;27(7):609–14.
26. Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955-‐1989. Gut. 1997 Oct;41(4):480–6.
27. Lapidus A. Crohn’s disease in Stockholm County during 1990-‐2001: an epidemiological update. World J Gastroenterol WJG. 2006 Jan 7;12(1):75–81.
28. Acheson ED. The distribution of ulcerative colitis and regional enteritis in United States veterans with particular reference to the Jewish religion. Gut. 1960;1(4):291–3.
29. Russell R., Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol. 2004 Jun;18(3):525–39.
30. Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ. 1996 Jan 13;312(7023):95–
6.
31. Orholm M, Binder V, Sørensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol.
2000 Oct;35(10):1075–81.
32. Leong RWL, Lau JY, Sung JJY. The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis. 2004 Sep;10(5):646–51.
33. Aujnarain A, Mack DR, Benchimol EI. The Role of the Environment in the Development of Pediatric Inflammatory Bowel Disease. Curr Gastroenterol Rep [Internet]. 2013 Jun [cited 2014 May 19];15(6). Available from: http://link.springer.com/10.1007/s11894-‐013-‐0326-‐4 34. Baron S. Environmental risk factors in paediatric inflammatory bowel diseases: a population
based case control study. Gut. 2005 Mar 1;54(3):357–63.
35. Bridger S, Lee JCW, Bjarnason I, Jones JL, Macpherson AJ. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-‐smokers develop ulcerative colitis. Gut. 2002;51(1):21–5.
36. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344(11):808–14.
37. Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P. Psychological issues in inflammatory bowel disease: an overview. Gastroenterol Res Pract. 2012;2012:106502.
38. Hollander D. Inflammatory bowel diseases and brain-‐gut axis. J Physiol Pharmacol Off J Pol Physiol Soc. 2003 Dec;54 Suppl 4:183–90.
39. Maunder RG, Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med. 2008 Jun;8(4):247–
52.
40. Bernstein CN. Epidemiologic Clues to Inflammatory Bowel Disease. Curr Gastroenterol Rep.
2010 Dec;12(6):495–501.
41. Cho JH, Brant SR. Recent Insights Into the Genetics of Inflammatory Bowel Disease.
Gastroenterology. 2011 May;140(6):1704–1712.e2.
42. Brant SR. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013 Jan;11(1):22–6.
43. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature.
2012 Oct 31;491(7422):119–24.
44. Blum RW. Chronic illness and disability in adolescence. J Adolesc Health Off Publ Soc Adolesc Med. 1992 Jul;13(5):364–8.
45. Okumura MJ, Heisler M, Davis MM, Cabana MD, Demonner S, Kerr EA. Comfort of general internists and general pediatricians in providing care for young adults with chronic illnesses of childhood. J Gen Intern Med. 2008 Oct;23(10):1621–7.
46. Kent RM, Chamberlain MA. Transition from paediatric to adult neurological services. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1208; author reply 1208.
47. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflamm Bowel Dis. 2011 Jun;17(6):1314–21.
48. Gower-‐Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, et al.
Epidemiology of inflammatory bowel diseases: New insights from a French population-‐
based registry (EPIMAD). Dig Liver Dis. 2013 Feb;45(2):89–94.
49. Ruel J, Ruane D, Mehandru S, Gower-‐Rousseau C, Colombel J-‐F. IBD across the age spectrum-‐is it the same disease? Nat Rev Gastroenterol Hepatol. 2014 Feb;11(2):88–98.
50. Gasparetto M, Guariso G. Highlights in IBD Epidemiology and Its Natural History in the Paediatric Age. Gastroenterol Res Pract. 2013;2013:1–12.
51. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al.
Definition of phenotypic characteristics of childhood-‐onset inflammatory bowel disease.
Gastroenterology. 2008 Oct;135(4):1114–22.
52. Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Winter HS, Baldassano RN, et al. Gender Differences in Presentation and Course of Disease in Pediatric Patients With Crohn Disease.
PEDIATRICS. 2007 Dec 1;120(6):e1418–e1425.
53. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM.
Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011 Jan;17(1):423–39.
54. Armitage E, Drummond H, Ghosh S, Ferguson A. Incidence of juvenile-‐onset Crohn’s disease in Scotland. The Lancet. 1999;353(9163):1496–7.
55. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: a statewide population-‐based study. J Pediatr. 2003 Oct;143(4):525–31.
56. Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V, et al. Epidemiology of inflammatory bowel disease: is there a shift towards onset at a younger age? J Pediatr Gastroenterol Nutr. 2011;53(2):141–4.
57. De Ridder L, Weersma RK, Dijkstra G, van der Steege G, Benninga MA, Nolte IM, et al.
Genetic susceptibility has a more important role in pediatric-‐onset Crohn’s disease than in adult-‐onset Crohn’s disease. Inflamm Bowel Dis. 2007 Sep;13(9):1083–92.
58. Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne J-‐E, et al. Natural history of elderly-‐onset inflammatory bowel disease: a population-‐based cohort study. Gut. 2014 Mar;63(3):423–32.
59. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-‐onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD consortium registry. J Pediatr. 2005 Jan;146(1):35–40.
60. Weiss B, Shamir R, Bujanover Y, Waterman M, Hartman C, Fradkin A, et al. NOD2/CARD15 mutation analysis and genotype-‐phenotype correlation in Jewish pediatric patients compared with adults with Crohn’s disease. J Pediatr. 2004 Aug;145(2):208–12.
61. Glocker E-‐O, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-‐10 receptor. N Engl J Med.
2009;361(21):2033–45.
62. Jost T, Lacroix C, Braegger CP, Chassard C. New insights in gut microbiota establishment in healthy breast fed neonates. PloS One. 2012;7(8):e44595.
63. Hutfless S, Li D-‐K, Heyman MB, Bayless TM, Abramson O, Herrinton LJ. Prenatal and perinatal characteristics associated with pediatric-‐onset inflammatory bowel disease. Dig Dis Sci. 2012 Aug;57(8):2149–56.
64. Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring’s risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis. 2012 May;18(5):857–62.
65. Bengtson M-‐B, Solberg IC, Aamodt G, Jahnsen J, Moum B, Vatn MH, et al. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm Bowel Dis. 2010 May;16(5):847–
55.
66. Roberts SE, Wotton CJ, Williams JG, Griffith M, Goldacre MJ. Perinatal and early life risk factors for inflammatory bowel disease. World J Gastroenterol WJG. 2011 Feb 14;17(6):743–9.
67. Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review:
the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr. 2009 Sep;155(3):421–6.
68. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-‐analysis. Am J Clin Nutr. 2004 Nov;80(5):1342–52.
69. Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, et al. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn’s disease: a case-‐control study.
Am J Gastroenterol. 2006 May;101(5):1005–11.
70. Hampe J, Heymann K, Krawczak M, Schreiber S. Association of inflammatory bowel disease with indicators for childhood antigen and infection exposure. Int J Colorectal Dis. 2003 Sep;18(5):413–7.
71. Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, et al. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol. 2010 Nov;105(11):2412–9.
72. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol.
1993 Mar;88(3):356–9.
73. Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis. 2007 Apr;13(4):431–8.
74. Vernier–Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural History of Pediatric Crohn’s Disease: A Population-‐Based Cohort Study. Gastroenterology.
2008 Oct;135(4):1106–13.
75. Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Gold BD, Cohen SA, et al. Incidence of stricturing and penetrating complications of Crohnʼs disease diagnosed in pediatric patients:
Inflamm Bowel Dis. 2010 Apr;16(4):638–44.
76. Malaty H, Abraham, Seema Mehta, Garnett E, Ferry. The natural history of ulcerative colitis in a pediatric population: a follow-‐up population-‐ based cohort study. Clin Exp Gastroenterol. 2013 Jun;77.
77. Schaeffer DF, Win LL, Hafezi-‐Bakhtiari S, Cino M, Hirschfield GM, El-‐Zimaity H. The Phenotypic Expression of Inflammatory Bowel Disease in Patients with Primary Sclerosing Cholangitis Differs in the Distribution of Colitis. Dig Dis Sci. 2013 Sep;58(9):2608–14.
78. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr. 2005;40(3):262–72.
79. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007 Aug;133(2):423–32.
80. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr.
1991 May;12(4):439–47.
81. Markowitz J, Grancher K, Kohn N, Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-‐2000. Am J Gastroenterol.
2002 Apr;97(4):928–32.
82. Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Paediatr Scand Suppl. 1990;366:98–104; discussion 105.
83. Markowitz J, Daum F. Growth impairment in pediatric inflammatory bowel disease. Am J Gastroenterol. 1994 Mar;89(3):319–26.
84. Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease.
Lancet. 1971 Dec 11;2(7737):1273–6.
85. Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology. 1974 May;66(5):916–22.
86. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-‐
mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease.
Gastroenterology. 2000 Oct;119(4):895–902.
87. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, et al. Tumour-‐necrosis-‐
factor antibody treatment in Crohn’s disease. The Lancet. 1993;342(8864):173–4.
88. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-‐to-‐Severe Crohn’s Disease in Children. Gastroenterology. 2007 Mar;132(3):863–73.
89. Lügering A, Schmidt M, Lügering N, Pauels H-‐G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-‐dependent pathway. Gastroenterology. 2001 Nov;121(5):1145–57.
90. Van den Brande JM., Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-‐lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003 Jun;124(7):1774–85.
91. Guagnozzi D, González-‐Castillo S, Olveira A, Lucendo AJ. Nutritional treatment in inflammatory bowel disease. An update. Rev Esp Enferm Dig. 2012;104(9):479–88.
92. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet. 2007;369(9573):1641–57.
93. Abraham BP, Mehta S, El-‐Serag HB. Natural history of pediatric-‐onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol. 2012 Aug;46(7):581–9.
94. Boualit M, Salleron J, Turck D, Fumery M, Savoye G, Dupas J-‐L, et al. Long-‐term outcome after first intestinal resection in pediatric-‐onset Crohn’s disease: a population-‐based study.
Inflamm Bowel Dis. 2013 Jan;19(1):7–14.
95. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr. 2000 Aug;137(2):192–6.
96. Ruemmele FM. Infliximab: how to use it in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr. 2004;39(1):12–4.
97. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-‐
term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337(15):1029–36.
98. De Ridder L, Escher JC, Bouquet J, Schweizer JJ, Rings EH, Tolboom JJ, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr. 2004;39(1):46–52.
99. Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, et al. Adalimumab in the treatment of immune-‐mediated diseases. Int J Immunopathol Pharmacol. 2014 Mar;27(1 Suppl):33–48.
100. Lazzerini M, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, et al. Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease: A Randomized Clinical Trial. JAMA. 2013 Nov 27;310(20):2164.
101. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-‐based study.
Gastroenterology. 2001 Aug;121(2):255–60.
102. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-‐year follow-‐up. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):298–
301.
103. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review: The mode of action of GMA. Clin Exp Immunol. 2011 Jan;163(1):50–8.
104. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol.
1991 Dec;86(3):489–93.
105. Habermalz B, Sauerland S. Clinical Effectiveness of Selective Granulocyte, Monocyte Adsorptive Apheresis with the Adacolumn® Device in Ulcerative Colitis. Dig Dis Sci. 2010 May;55(5):1421–8.
106. Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn?s disease: an open multicenter prospective study. J Gastroenterol. 2004 Dec;39(12):1158–64.
107. Hyams JS, Davis P, Grancher K, Lerer T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996 Jul;129(1):81–8.
108. Alexander F, Sarigol S, DiFiore J, Stallion A, Cotman K, Clark H, et al. Fate of the pouch in 151 pediatric patients after ileal pouch anal anastomosis. J Pediatr Surg. 2003 Jan;38(1):78–82.
109. Sarigol S, Caulfield M, Wyllie R, Alexander F, Lavery I, Steffen R, et al. Ileal pouch-‐anal anastomosis in children with ulcerative colitis. Inflamm Bowel Dis. 1996;2(2):82–7.
110. Evans JG, Acheson ED. An epidemiological study of ulcerative colitis and regional enteritis in the Oxford area. Gut. 1965;6(4):311.
111. Hassan K, Cowan FJ, Jenkins HR. The incidence of childhood inflammatory bowel disease in Wales. Eur J Pediatr. 2000;159(4):261–3.
112. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88(11):995–1000.
113. Jussila A, Virta LJ, Salomaa V, Mäki J, Jula A, Färkkilä MA. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference. J Crohns Colitis.
2013 Aug;7(7):e256–e262.
114. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, et al. Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-‐Based Study from Copenhagen, Denmark: Inflamm Bowel Dis. 2007 Apr;13(4):481–9.
